Executive Chair; Former President and Chief Executive Officer · Anika Therapeutics, Inc. (ANIK)

Cheryl Blanchard

A named executive officer of Anika Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$4,887,318

FY2024: $5,103,466

1st of 5 named executive officers at Anika Therapeutics by FY2025 total.

5 named officers on file for Anika Therapeutics, FY2025

See an example →

What this number hides

The filing gives the total. Anika Therapeutics’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how Anika Therapeutics’s whole pay program stands against its peers

  • Anika Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ANIK→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2026 (DEF 14A).

Free

Get Cheryl Blanchard’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Cheryl Blanchard and every company like it: Velarion Intel, free for 3 days, no card →

Cheryl Blanchard compensation by year

Anika Therapeutics Summary Compensation Table · all 6 fiscal years held
In US dollars, as Anika Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023FY2024FY2025
Salary$548,077$668,400$695,100$726,000$743,943$750,397
Bonus$458,510$568,140$590,835$583,160$497,513$638,000
Stock awards$5,335,439$1,470,806$2,306,779$1,614,708$1,918,049$3,476,669
Option awards$3,659,450$1,471,831$2,323,562$1,509,736$1,915,059$0
Non-equity incentive$0$0$0$0$0$0
Pension and deferred compensation$0$0$0$0$0$0
All other$27,958$23,431$24,446$26,196$28,902$22,252
Total$10,029,434$4,202,608$5,940,722$4,459,800$5,103,466$4,887,318

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Anika Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001140361-26-017488, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Anika Therapeutics, Inc. filed document, accession 0001140361-26-017488. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.

$10.0M
$4.2M
$5.9M
$4.5M
$5.1M
$4.9M
FY20
FY21
FY22
FY23
FY24
FY25
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU73,559$706,902—
RSU71,403$686,183—
RSU60,900$585,249—

Per the Outstanding Equity Awards at Fiscal Year-End table in Anika Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Anika Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Cheryl Blanchard · this pageExecutive Chair; Former President and Chief Executive Officer$4,887,318
Stephen GriffinPresident and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer$2,033,370
David ColleranExecutive Vice President, General Counsel and Secretary$1,614,205
Anne NunesFormer Senior Vice President, Chief Operations Officer$946,571
Ian McLeodSenior Vice President, Chief Accounting Officer and Treasurer$765,544

Board service

Anika Therapeutics board · FY2024–FY2025

How this board is paid

Company policy: Anika Therapeutics pays directors a $50,000 cash retainer and $149,997 in RSUs. As stated in Anika Therapeutics's FY2025 proxy.

Cheryl Blanchard's compensation dossier, Anika Therapeutics

You have read Cheryl Blanchard's totals and holdings. The dossier adds each equity grant Anika Therapeutics disclosed for Cheryl Blanchard and Anika Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full Anika Therapeutics compensation record

free company brief

This page is one person within Anika Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Anika Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Anika Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Anika Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order ANIK

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Cheryl Blanchard's compensation dossier